CemiplimAb Survivorship Epidemiology
Public ClinicalTrials.gov record NCT03836105. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Cemiplimab Survivorship Epidemiology (CASE) Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objectives of the study are: * To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) cutaneous squamous cell carcinoma (CSCC) and patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) basal cell carcinoma (BCC) in real-world clinical settings * To evaluate the safety of cemiplimab based on incidence of treatment related immune-related adverse events (irAEs), infusion related reactions (IRRs), and treatment related serious adverse reactions (TSARs) in patients with advanced CSCC and patients with advanced BCC receiving cemiplimab treatment in real world clinical settings * To describe patient experience, including patient reported quality of life (QOL) and functional status, and clinician reported performance status in a real-world setting for patients with advanced CSCC and patients with advanced BCC * To describe baseline characteristics that could potentially be associated with health-related outcomes for patients with advanced CSCC and patients with advanced BCC undergoing treatment with cemiplimab * To describe patients who receive cemiplimab as treatment for CSCC or BCC in a real-world setting * To describe real-world use patterns of cemiplimab for CSCC and BCC * To investigate the long-term effects and effectiveness of cemiplimab in patients with advanced CSCC or advanced BCC * To describe the effectiveness of cemiplimab in immunosuppressed and immunocompetent patients with advanced CSCC or advanced BCC, regardless of etiology, per available data * To describe the effectiveness of cemiplimab after prior exposure to radiation therapy for CSCC per available data * To describe the effectiveness of cemiplimab as a first-line (1L) or later systemic treatment in patients with advanced CSCC, regardless of etiology, per available data * To describe the effectiveness of cemiplimab in patients with advanced BCC based on treatment patterns (reason for discontinuation, treatment exposure, etc) of prior Hedgehog inhibitor (HHI) usage
Study identification
- NCT ID
- NCT03836105
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 287 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 26, 2019
- Primary completion
- Sep 28, 2025
- Completion
- Sep 28, 2025
- Last update posted
- Oct 14, 2025
2019 – 2025
United States locations
- U.S. sites
- 51
- U.S. states
- 26
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Oncology Specialties, PC - Clearview Cancer Institute | Huntsville | Alabama | 35805 | — |
| Dignity Health St. Joseph's Hospital and Medical Center | Phoenix | Arizona | 85013 | — |
| CARTI Cancer Center | Little Rock | Arkansas | 72205 | — |
| University of California San Diego | La Jolla | California | 92037 | — |
| Harbor-UCLA/LA Biomedical Research Institute | Los Angeles | California | 90502 | — |
| St. Mary's Medical Center | San Francisco | California | 94117 | — |
| Regeneron Research Facility | Stanford | California | 94063 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| The Melanoma and Skin Cancer Institute | Englewood | Colorado | 80113 | — |
| Regional Cancer Care Associates, LLC | Manchester | Connecticut | 06040 | — |
| Integrity Clinical Research | Delray Beach | Florida | 33745 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Regeneron Research Facility | Largo | Florida | 33770 | — |
| Regeneron Research Facility | Miami | Florida | 33156 | — |
| Miami Cancer Institute at Baptist Health, Inc. | Miami | Florida | 33176 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital | Thomasville | Georgia | 31792 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| NorthShore University HealthSystem | Evanston | Illinois | 60201 | — |
| Reid Oncology Association | Richmond | Indiana | 47374 | — |
| CHRISTUS Highland Cancer Treatment Center | Shreveport | Louisiana | 71105 | — |
| Baltimore Veterans Affairs Medical Center | Baltimore | Maryland | 21201 | — |
| Frederick Health | Frederick | Maryland | 21702 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Lahey Hospital & Medical Center | Burlington | Massachusetts | 01805 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Southeast Nebraska Hematology & Oncology Consultants, PC | Lincoln | Nebraska | 68510 | — |
| Optum Cancer Care | Las Vegas | Nevada | 89102 | — |
| Regeneron Research Facility | Elizabeth | New Jersey | 07202 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14203 | — |
| Regeneron Research Facility | New York | New York | 10016 | — |
| Regeneron Research Facility | New York | New York | 10032 | — |
| Regeneron Research Facility | Nyack | New York | 10960 | — |
| New York Cancer and Blood Specialists | Port Jefferson Station | New York | 11776 | — |
| Montefiore Hospital | The Bronx | New York | 10461 | — |
| Oncology Specialists of Charlotte, PA | Charlotte | North Carolina | 28204 | — |
| Durham VA Medical Center | Durham | North Carolina | 27705 | — |
| Asante Rogue Regional Medical Center | Medford | Oregon | 97504 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | 18015 | — |
| Clinical Research Center of the Carolinas | Charleston | South Carolina | 29407 | — |
| Charleston Hematology Oncology Associates, PA | Charleston | South Carolina | 29414 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Texas Oncology-Amarillo Cancer Center | Amarillo | Texas | 79106 | — |
| Texas Oncology | Dallas | Texas | 75246 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Renovatio Clinical | The Woodlands | Texas | 77380 | — |
| University of Vermont | Burlington | Vermont | 05401 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03836105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2025 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03836105 live on ClinicalTrials.gov.